ClinicalTrials.gg
RecruitingNCT06893887ICT-HCCUpdated Oct 1, 2026

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

An interventional study of FOLFOX4 and Adebrelimab in Hepatocellular Carcinoma(HCC), sponsored by Nanjing Tianyinshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Nanjing Tianyinshan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 1, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
270
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing adebrelimab in Carcinoma, Hepatocellular — 12 open to participants now, 12 under way, 1 of them phase 3. adebrelimab · Carcinoma, Hepatocellular.

Planned enrollment
2nd of 13
270 · median 52
Started
2025
with 2 others
No phase
Only one
of the 13
Primary completion
2027-12
later than 9 of 11 live
Registered
10th of 13
by date
Lead sponsor
1 of 13
Nanjing Tianyinshan Hospital

Among the 13 studies testing adebrelimab in Carcinoma, Hepatocellular, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2025, is the only one with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 10th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

12 of the 13 studies testing adebrelimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

About adebrelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing adebrelimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy. Based on different patterns of disease progression, patients will receive relevant systemic treatments, either with or without local interventional therapy. The primary endpoint is progression-free survival (PFS), while secondary endpoints include overall survival (OS), 1-year OS rate, objective response rate (ORR), disease control rate (DCR), duration of remission (DOR), and safety. Additionally, the study will explore the correlation between patients' clinical pathological characteristics, serum biomarkers, and clinical efficacy.

03

Conditions studied

  • Hepatocellular Carcinoma(HCC)
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old, male or female
  2. Hepatocellular carcinoma patients diagnosed by cytology or tissue puncture, or who meet clinical diagnostic criteria and cannot be treated with radical treatment (radical surgery, ablation, radiotherapy, etc.)
  3. Clinical disease progression after targeted combined immune system therapy ( or PD-L1 monoclonal antibody only)
  4. exceeds 3 months
  5. physical condition score 0\~1
  6. Women of childbearing age must have a serum pregnancy study done within 7 days before the first medication, and the result is negative. Female subjects of reproductive age and male subjects whose partners are women of reproductive age must consent to within 24 weeks from the date of signing the to the last administration of the study drug
  7. Before the first dose of the drug, the laboratory test values met the following conditions: ①blood routine (no blood transfusion within 14 days before screening, no hematopoietic stimulating drug correction) : white blood cell count (WBC) ≥ 2.0 × 109/L; (PLT) ≥ 60× 109/L; content (HGB) ≥ 8.0 g/dL; ② Liver function: aspartate transferase () ≤ 2.5x ; alanine aminotransferase (ALT) ≤ 2.5 x ULN; Serum total (TBIL) ≤ 1.5 x ULN (except Gilbert syndrome total bilirubin ≤ 3.0 mg/dL); ③ Renal function: serum creatinine ≤ 1.5 x ULN or rate (CrCl) ≥ 50 mL/minute; ④ Coagulation function: (INR) ≤ 1.5 x ULN, activated partial thromboplastin time (APTT) ≤ 1.5 x ULN (only for patients who are not currently receiving anticoagulant therapy, patients who are currently receiving anticoagulant therapy should receive a steady dose of anticoagulant therapy)
  8. The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with the follow-up

Exclusion criteria

Exclusion Criteria:

  1. Pathological types of other non-hepatocellular carcinomas, including fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, etc. previously confirmed by histology/cytology
  2. grade of liver function> 7 points
  3. Major cardiovascular impairment in the 6 months prior to initial administration of the drug, such as a (NYHA) Class II or higher history of congestive heart failure, unstable angina, myocardial infarction or stroke, or arrhythmia associated with hemodynamic instability; (QTc) interval lengthening >480ms
  4. Other developed ≤ 5 years before the first dose, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery (hormone therapy for non- prostate cancer or breast cancer is allowed)
  5. Have had an active disease in the past 2 years that requires systemic treatment, including but not limited to autoimmune hepatitis, lupus erythematosus, etc
  6. Uncontrolled active infection, such as active tuberculosis, infection, etc.; Patients with replication level below 10000IU/mL and continuous oral antiviral therapy could be enrolled.
  7. Had undergone major surgery in the 28 days prior to randomization or planned to undergo major surgery during the study period
  8. Use of within 28 days prior to randomization, or anticipated use of such live attenuated vaccine during the study period (patients are not allowed to receive live attenuated influenza vaccine 4 weeks prior to randomization, during treatment, and within 5 months after the final administration of adbelizumab)
  9. Received any other drug treatment or participated in another interventional clinical study within 4 weeks prior to signing the ICF
  10. Use of (> 10 mg/ day prednisone or equivalent dose) or other within ≤ 14 days prior to the first dose of the study drug. Allowing inhaled or topical use of steroids and adrenal replacement steroids in the absence of active autoimmune disease; Patients received systemic immunosuppressive drugs (including but not limited to glucocorticoids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] drugs) within 1 week prior to randomization. Patients receiving short-term, systemic immunosuppressant therapy, such as glucocorticoids for nausea, vomiting, or anaphylaxis management or prevention, may be enrolled in the study after investigator review. To allow the use of inhaled corticosteroids in patients with , corticosteroids such as fluhydrocortisone in patients with postural hypotension, and low-dose glucocorticoid supplements for adrenal insufficiency; Known mental illness, alcoholism, inability to quit smoking, drug or substance abuse
  11. In the investigator's judgment, the subjects have other factors that may lead to the forced termination of the study, such as non-compliance with the protocol, other serious illnesses (including mental illness) requiring combined treatment, serious laboratory abnormalities, family or social factors that may affect the safety of the subjects, or the collection of data and samples
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Arm 1

    XELOX/FOLFOX4+ Adebelizumab + Apatinib+Icaritin

    Drug: FOLFOX4 · Drug: Adebrelimab

  • Experimental
    Arm 2

    Adebelizumab + Apatinib+Icaritin

    Drug: Adebrelimab · Drug: Apatinib · Drug: Icaritin

  • Experimental
    Arm 3a

    QL1706+ Apatinib+Icaritin

    Drug: Apatinib · Drug: Icaritin · Drug: QL1706

  • Experimental
    Arm 3b

    Retlirafusp alfa+ Apatinib+Icaritin

    Drug: Apatinib · Drug: Icaritin · Drug: Retlirafusp alfa

  • Experimental
    Arm 4

    The original targeted combination immunotherapy+HAIC

    Drug: Apatinib · Drug: Icaritin · Drug: QL1706 · Procedure: HAIC · Drug: The original treatment regimen

  • Experimental
    Arm 5a

    QL1706+ Apatinib+Icaritin

    Drug: Apatinib · Drug: Icaritin · Drug: QL1706

  • Experimental
    Arm 5b

    Retlirafusp alfa+ Apatinib+Icaritin

    Drug: Apatinib · Drug: Icaritin · Drug: Retlirafusp alfa

  • Experimental
    Arm 6a

    QL1706+Bevacizumab+Icaritin

    Drug: Icaritin · Drug: QL1706 · Drug: Bevacizumab

  • Experimental
    Arm 6b

    Retlirafusp alfa+Bevacizumab+Icaritin

    Drug: Icaritin · Drug: Retlirafusp alfa · Drug: Bevacizumab

Interventions

  • DrugFOLFOX4

    FOLFOX4 was administered by oxaliplatin 85 mg/m² d1+ leucovorin 200 mg/m² d1-2+ fluorouracil 400 mg/m² 2 h→ 600 mg/m² 24 h d1-2 q2w, with a total of 4 cycles

  • Adebrelimab 1200mg, intravenous infusion, every 3 weeks

  • Apatinib 250mg, oral, once daily.

  • Epimedium extract soft capsules 2.4g, oral, 2 times daily.

  • DrugSHR-1701Studies of SHR-1701SHR-1701 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Retlirafusp alfa,1800mg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

  • DrugIparomlimab/TuvonralimabStudies of Iparomlimab/TuvonralimabIparomlimab/Tuvonralimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

  • Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks.

  • ProcedureHAIC

    Hepatic Arterial Infusion Chemotherapy

  • DrugThe original treatment regimen

    Continue the original targeted therapy combined with immunotherapy. dosage, dosage form,frequency of administration was the same as before.

06

What researchers measure

Primary outcomes

  1. PFS(Progression-free Survival)

    Progression-free survival (PFS) was defined as the time from treatment initiation on Day 1 to the earliest occurrence of radiologically confirmed disease progression, as assessed by tumor imaging, or death from any cause, whichever came first. Evaluations were conducted by the investigator in accordance with RECIST v1.1.

    Time frame: 24 months

Secondary outcomes

  1. OS(Overall survival)

    Overall survival (OS) was defined as the duration from treatment initiation on Day 1 to death from any cause.

    Time frame: 48 months

  2. ORR(Objective response rate)

    Objective response rate (ORR) was defined as the proportion of subjects achieving a complete response (CR) or partial response (PR), as assessed by the investigator according to RECIST v1.1, from the initiation of treatment on Day 1.

    Time frame: 24 months

  3. DCR(Disease control rate )

    Disease control rate (DCR) was defined as the proportion of subjects achieving a complete response (CR), partial response (PR), or stable disease (SD) lasting ≥8 weeks, as assessed by the investigator according to RECIST v1.1, from the initiation of treatment on Day 1.

    Time frame: 24 months

  4. DOR(Duration of Response)

    Duration of response (DOR) was defined as the time from the first documented objective response (CR or PR) to the earliest occurrence of radiological disease progression or death from any cause, whichever occurred first. Both response and progression were evaluated by the investigator according to RECIST v1.1.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
  • China Pharmaceutical University Affiliated Nanjing Tianyinshan Hospital
    Nanjing, Jiangsu 210000, China
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 30 months is below that.

Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Mar 2027 → Dec 2027 and completion Mar 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 25, 2025
StartActual
May 22, 2025
Primary completionEst.
Dec 15, 2027was Mar 2027
CompletionEst.
Dec 15, 2028was Mar 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 15, 2027→Dec 15, 2027
Oct 1, 2026
Study completion
Mar 15, 2028→Dec 15, 2028
Oct 1, 2026
Enrollment
300→270
Oct 1, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedDiseaseClinical disease progression after first-line targeted combined immune system therapy (as per RECIST1.PD-1 criteriaor PD-L1 monoclonal antibody only)
Exclusion criteria
  • EditedChild-Pugh grade of liver function ≥> 7 points
Oct 1, 2026
Interventions
Added Drug: Retlirafusp alfa; removed Drug: SHR-1701·Procedure: Local treatment. Arm changed Arm 9→Arm 6a; Arm 3→Arm 3a; Arm 5→Arm 5a; Arm 6→Arm 6b. Arms added: Arm 3b·Arm 5b; arms removed: Arm 7·Arm 8·Arm 10
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Primary completion Mar 15, 2027→Dec 15, 2027
    Study completion Mar 15, 2028→Dec 15, 2028
    Enrollment 300→270
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedDiseaseClinical disease progression after first-line targeted combined immune system therapy (as per RECIST1.PD-1 criteriaor PD-L1 monoclonal antibody only)
    Exclusion criteria
    • EditedChild-Pugh grade of liver function ≥> 7 points
    Interventions Added Drug: Retlirafusp alfa; removed Drug: SHR-1701·Procedure: Local treatment. Arm changed Arm 9→Arm 6a; Arm 3→Arm 3a; Arm 5→Arm 5a; Arm 6→Arm 6b. Arms added: Arm 3b·Arm 5b; arms removed: Arm 7·Arm 8·Arm 10
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06893887
Lead sponsor
Nanjing Tianyinshan Hospital
Responsible party
Sponsor
First posted
Mar 25, 2025
Start date
May 22, 2025
Primary completion
Dec 15, 2027 (estimated)
Completion
Dec 15, 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Chen Xun
Contact
mxrlwx19911990@163.com
+86-13851670770

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adebrelimab · Apatinib · Icaritin · SHR-1701 · Iparomlimab/Tuvonralimab · Bevacizumab

Start the discussion